A. Vita, 23andMe : La FDA approuve la vente de tests génétiques sans conseil médical, http://www.alliancevita.org/2017/04/23-and-me-la-fda-approuve-la-vente-de-tests- genetiques-sans-conseil-medical, 2017.

A. Iervolino, L. Urquhart, and . World, Outlook to 2022, EvaluatePharma, 2017.

R. Anderson, . Bbc, and . News, Pharmaceutical industry gets high on fat profits

M. Biery and . Forbes, The Most Profitable Industries In 2016, https://www.forbes.com/sites/sageworks/2016/08/06/the-most-profitable-industries, 2016.

L. Vitez, R. Harrison, and . Biopharmadealmakers, Trends in pharmaceutical mergers and acquisitions, https://biopharmadealmakers.nature.com/users/9880-biopharma- dealmakers/posts/13880-trends-in-pharmaceutical-mergers-and-acquisitions, 2017.

. Consultancy, Ten year deal activity in pharmaceuticals industry stands at $2.4 trillion, https://www.consultancy.uk/news/13046/ten-year-deal-activity-in-pharmaceuticals-industry- stands-at-24-trillion, 2017.

S. Mukherjee and . Fortune, These Were the 10 Biggest Pharmaceutical Deals of 2016, 2016.

C. Koons, E. Hammond, D. Armstrong, and . Bloomberg, Inside the $21 Billion War for a Blockbuster Cancer Drug, https://www.bloomberg.com/news/articles/2015-03-05/abbvie-emerges-with-21- billion-deal-in-fight-to-the-very-end, 2017.

M. M. Benson and . Realist, What it takes to be called 'big pharma, 2017.

S. F. King and . Pharma, Roche's near-term biosimilar threat in Europe

M. Herper and . Forbes, Who's The Best In Drug Research? 22 Companies Ranked, https://www.forbes.com/sites/matthewherpernew-report-ranks-22-drug- companies-based-on-rd/#567dd38d4268, 2014.

L. E. Palich, L. Cardinal, C. Miller, and C. , Curvilinearity in the diversification-performance linkage: an examination of over three decades of research, Strategic Management Journal, vol.9, issue.2, pp.155-174, 2000.
DOI : 10.1002/smj.4250090502

C. C. Markides, Consequences of corporate refocusing: Ex ante evidence, Academy of Management Journal, pp.398-412, 1992.

C. W. Hill and G. S. Hansen, A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry, pp.187-199, 1977.

M. Macaluso, The Motley Fool, Big Pharma Diversification: A Winning Model or Recipe for Disaster?, https://www.fool.com/investing/general, 2014.

J. Gilbert, P. Henske, and A. Singh, Rebuilding Big Pharma's Business Model, In Vivo, The Business & Medicine report, 2003.

M. Cha and T. Lorriman, Why pharma megamergers work, https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/ourinsights/why-pharma-megamergers-work, McKinsey & Company report, 2017.

G. View and R. , Vaccine Market Analysis by type, http://www.grandviewresearch.com/industry-analysis/vaccine-market, consulté en septembre, 2017.

&. Mckinsey and . Company, Generating value in generics: Finding the next 5 years growth

R. Berger and S. Consultants, Fight or flight? Diversification vs. Rx-focus in big pharma's quest for sustained growth

T. Van-biesen, T. Johnson, P. O-'hagan, &. Bain, and . Company, The Power of focus, http://www.bain.com/publications/articles/the-power-of-focus-in-medical-technology.aspx, 2017.

S. Goodall, E. Olsen, S. Staats, and P. Tollman, The Boston Consulting Group, Capitalizing on the crisis: New Ways to Create Value in Biopharma

M. Russell, M. Gjaja, and P. Lawyer, The Boston Consulting Group, The Future of Pharma: Adjusting the Pharma R&D Model, 2017.

J. Cacciotti, B. Shew, and P. Garg, New Ecosystems in Pharma: Maturing markets mean new models are needed, In Vivo: The Business & Medicine report, 2012.

J. Paillé and L. Tribune, Les géants pharmaceutiques absents du Top 10 des labos les plus innovants, http://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/les-geants- pharmaceutiques-absents-du-top-10-des-labos-les-plus-innovants-554264, 2017.

. Igeahub, Top 10 Pharmaceutical Companies 2017, https://igeahub.com, 2017.

R. Smid, S. Binns, S. Boehme, M. Bohme, F. Guilbaud et al., Working Capital: never been better, What the top performing companies are doing differently

P. Piget, Analyse financière en IFRS, Economica, 2011.